Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01323920 · ClinicalTrials.gov registry record · Phase 2
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT01323920 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 35 participants.
The verdict
NCT01323920, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
A common problem after stem cell transplant is graft-versus-host-disease (GVHD). GVHD is a complication of transplantation where the donor graft attacks and damages some of your tissues. After stem cell transplant, all patients receive prophylactic medications against GVHD. In this research study, we are studying the safety and effectiveness of a bortezomib based GVHD prophylaxic drug combination in participants after myeloablative allogeneic stem call transplantation from a matched unrelated donor, mismatched related or unrelated donor.
Interventions
- DRUG Tacrolimus
- DRUG Bortezomib
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-05 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01323920
The ClinicalTrials.gov registry entry for NCT01323920 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tacrolimus is the first listed.
NCT01323920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01323920 about?
NCT01323920 is a clinical study titled "Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors". A common problem after stem cell transplant is graft-versus-host-disease (GVHD). GVHD is a complication of transplantation where the donor graft attacks and damages some of your tissues. After stem cell transplant, all patients receive prophylactic medications against GVHD. In this research study, ...
What is the current status of trial NCT01323920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2011-05. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01323920?
The interventions under investigation include: Tacrolimus (DRUG), Bortezomib (DRUG), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT01323920?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.